Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Traumatic intracranial aneurysms.

• Paul Sloan Larson, Andrew T. Reisner, Dante J. Morassutti, Basmah S. Abdulhadi, Jayme Harpring
• Neurosurgical focus
• 2000

Traumatic intracranial aneurysms are rare, occurring in fewer than 1% of patients with cerebral aneurysms. They can occur following blunt or penetrating head trauma and are more common in the… (More)

Long Term Toxicologic Assessment of Nickel in Rats and Dogs

• Anthony Ambrose, Paul Sloan Larson, Joseph Francis Borzelleca, Gordon R. Hennigar

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

• William J. Marks, Raymond T. Bartus, +23 authors C. Warren Olanow
• The Lancet. Neurology
• 2010

BACKGROUND In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor function in… (More)

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

• William J. Marks, Jill Louise Ostrem, +8 authors Raymond T. Bartus
• The Lancet. Neurology
• 2008

BACKGROUND There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect… (More)

Deep brain stimulator hardware-related infections: incidence and management in a large series.

• Karl A. Sillay, Paul Sloan Larson, Philip A. Starr
• Neurosurgery
• 2008

OBJECTIVE Device-related infection is a common complication of deep brain stimulator (DBS) implantation. We reviewed the incidence and management of early hardware-related infections in a large… (More)

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

• Câline Christine, Philip A. Starr, +7 authors Maria Aminoff
• Neurology
• 2009

BACKGROUND In Parkinson disease (PD), the benefit of levodopa therapy becomes less marked over time, perhaps because degeneration of nigrostrial neurons causes progressive loss of aromatic l-amino… (More)

Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.

• J. J. Zhao, J. D. Rogers, +7 authors H. Cheng
• Biopharmaceutics & drug disposition
• 1997

A study was conducted to (i) characterize the multiple-dose pharmacokinetics of oral montelukast sodium (MK-0476), 10 mg d-1 in healthy young subjects (N = 12), (ii) evaluate the pharmacokinetics of… (More)

The nature and course of olfactory deficits in Alzheimer's disease.

• Michael D Serby, Paul Sloan Larson, Davina Kalkstein
• The American journal of psychiatry
• 1991

OBJECTIVE The aim of this study was to determine the specific nature and course of olfactory deficits in Alzheimer's disease. Previous studies had noted impaired odor identification, but there was no… (More)

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

• Elizabeth M Migoya, Renée Bergeron, +19 authors Ranabir Sinharoy
• Clinical pharmacology and therapeutics
• 2010

The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. Active… (More)

Abnormal T2-weighted MRI signal surrounding leads in a subset of deep brain stimulation patients.

• Dario J Englot, Christine M Glastonbury, Paul Sloan Larson
• Stereotactic and functional neurosurgery
• 2011

BACKGROUND Deep brain stimulation (DBS) surgery is a common treatment option for numerous neurological disorders. However, it is not without potential complications, such as hemorrhage and infection.… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›